Healthcare - Biotechnology - NASDAQ - AU
$ 2.05
-1.91 %
$ 313 M
Market Cap
-8.2
P/E
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors.[ Read More ]
The intrinsic value of one IMMP stock under the base case scenario is HIDDEN Compared to the current market price of 2.05 USD, Immutep Limited is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart IMMP
FINANCIALS
3.84 M
REVENUE
-88.1 M
OPERATING INCOME
-42.7 M
NET INCOME
-34.8 M
OPERATING CASH FLOW
-21 M
INVESTING CASH FLOW
95.2 M
FINANCING CASH FLOW
1.73 M
REVENUE
-44.5 M
OPERATING INCOME
-21.5 M
NET INCOME
-16.4 M
OPERATING CASH FLOW
-20 M
INVESTING CASH FLOW
95.7 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Immutep Limited
| Current Assets | 191 M |
| Cash & Short-Term Investments | 182 M |
| Receivables | 7.56 M |
| Other Current Assets | 1.92 M |
| Non-Current Assets | 10.2 M |
| Long-Term Investments | 0 |
| PP&E | 680 K |
| Other Non-Current Assets | 9.55 M |
| Current Liabilities | 10.5 M |
| Accounts Payable | 3.79 M |
| Short-Term Debt | 234 K |
| Other Current Liabilities | 6.46 M |
| Non-Current Liabilities | 1.57 M |
| Long-Term Debt | 1.36 M |
| Other Non-Current Liabilities | 211 K |
EFFICIENCY
Earnings Waterfall
Immutep Limited
| Revenue | 3.84 M |
| Cost Of Revenue | 41.5 M |
| Gross Profit | -37.7 M |
| Operating Expenses | 50.4 M |
| Operating Income | -88.1 M |
| Other Expenses | -45.4 M |
| Net Income | -42.7 M |
RATIOS
-981.42%
GROSS MARGIN
-2293.26%
OPERATING MARGIN
-1111.87%
NET MARGIN
-22.54%
ROE
-21.19%
ROA
-46.25%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Immutep Limited
| Net Income | -42.7 M |
| Depreciation & Amortization | 2.26 M |
| Capital Expenditures | -932 K |
| Stock-Based Compensation | 1.8 M |
| Change in Working Capital | 3.46 M |
| Others | 3.24 M |
| Free Cash Flow | -35.8 M |
Wall Street Analysts Price Targets
Immutep Limited
Wall Street analysts predict an average 1-year price target for IMMP of $7.67 , with forecasts ranging from a low of $6 to a high of $10 .
IMMP Lowest Price Target
Wall Street Target
6 USD
192.68%
IMMP Average Price Target
Wall Street Target
7.67 USD
273.98%
IMMP Highest Price Target
Wall Street Target
10 USD
387.80%
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Immutep Limited
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients
Positive results from phase 1 INSIGHT-003 study, using eftilagimod alpha in combination with KEYTRUDA and chemotherapy in treating first-line metastatic non-squamous NSCLC patients. Additional data from the phase 1 INSIGHT-003 study is expected in 2025, with plans to initiate a phase 3 TACTI-004 study targeting the same patient population. The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031.
seekingalpha.com
- 1 day ago
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
On Thursday, Immutep Limited IMMP released data from the INSIGHT-003 Phase 1 trial of eftilagimod alpha (efti) in combination with Merck & Co Inc's MRK Keytruda (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients.
benzinga.com
- 2 days ago
Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 months, with median Progression Free Survival reaching 12.7 months, and a 24-month Overall Survival rate of 81.0% Data from all evaluable patients to date (N=40) demonstrates significant improvement of Overall Response Rate compared to historical controls Safety continues to be favourable with no new safety signals INSIGHT-003, which is nearing completion of enrolment, evaluates efti with the most widely used immunotherapy-chemo combination today in a similar population to upcoming TACTI-004 Phase III trial SYDNEY, AUSTRALIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive data from the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alpha (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer (1L NSCLC) patients. Prof. Dr. Salah-Eddin Al-Batran of the Frankfurt Institute of Clinical Cancer Research (IKF) and project lead stated, “The strength of these mature survival results coupled with a favourable safety profile in first-line treatment of patients with non-squamous NSCLC, the vast majority of whom have negative or low PD-L1 expression, is very encouraging.
globenewswire.com
- 2 days ago
Immutep Quarterly Activities Report Q1 FY25
SYDNEY, AUSTRALIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 30 September 2024 (Q1 FY25).
globenewswire.com
- 2 weeks ago
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces Marc Voigt, CEO of Immutep, will participate in a fireside chat at the Maxim Healthcare Virtual Summit on Wednesday, October 16, 2024 at 9:30 am ET. The fireside chat will be live on M-Vest.
globenewswire.com
- 1 month ago
Immutep: Navigating The Bumps In The Road
Immutep Limited (IMMP) has shown underwhelming results in their TACTI-003 trial, raising questions about the efficacy of their lead drug, eftilagimod. Despite the disappointing data, IMMP has a strong cash position, giving them a 3-4 year runway to continue their development efforts. The company remains a speculative investment with potential, especially with upcoming results from the AIPAC-003 breast cancer study expected in 2025.
seekingalpha.com
- 1 month ago
Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
SYDNEY, AUSTRALIA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive efficacy and safety results from the TACTI-003 Phase IIb trial evaluating eftilagimod alpha (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients (1L HNSCC).
globenewswire.com
- 2 months ago
Immutep Quarterly Activities Report Q4 FY24
Media Release Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line non-small cell lung cancer in a pivotal Phase III trial Continuing positive clinical data reported from efti: Positive results from TACTI-003 Phase IIb trial in first-line head and neck squamous cell carcinoma with efti in combination with KEYTRUDA® Encouraging efficacy and safety data from AIPAC-003 Phase II/III trial with efti and paclitaxel in metastatic breast cancer presented at ESMO Breast Cancer 2024 Novel triple combination of efti with radiotherapy and KEYTRUDA well tolerated with encouraging initial efficacy data in EFTISARC-NEO Phase II trial in soft tissue sarcoma Positive regulatory feedback received from Spanish Agency for Medicines and Health Products (AEMPS) Competent Authority regarding the upcoming TACTI-004 Phase III trial Appointed Centre for Human Drug Research (CHDR) to conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to treat autoimmune diseases Exclusive license agreement signed with Cardiff University for development of an orally available, small molecule anti-LAG-3 therapy to treat cancer A$100.2 million equity underwritten financing completed Immutep cash runway extended to the end of calendar year 2026, with a strong cash, cash equivalent and term deposit position totalling approximately A$181.8 million SYDNEY, AUSTRALIA, July 31, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 30 June 2024 (Q4 FY24). EFTI DEVELOPMENT PROGRAM FOR CANCER TACTI-004 (KEYNOTE-PNC91) – 1L NSCLC Phase III Clinical Collaboration with MSD In June, Immutep entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA), through a subsidiary, to evaluate efti in combination with MSD's anti-PD-1 therapy, KEYTRUDA and chemotherapy for a pivotal Phase III trial in first-line treatment of metastatic non-small cell lung cancer (1L NSCLC).
globenewswire.com
- 3 months ago
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
zacks.com
- 4 months ago
Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression
Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS
globenewswire.com
- 4 months ago
Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results
Company to Host Webcast on 12th July at 9am AEST (7pm ET, 11 July) SYDNEY, AUSTRALIA, July 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces details for an upcoming oral presentation at the European Society for Medical Oncology (ESMO) Virtual Plenary session on July 11, 2024, featuring new clinical data in patients with negative PD-L1 expression (Cohort B) in the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, and a webcast to discuss these clinical results. ESMO Virtual Plenaries are monthly presentations of the latest, original scientific data, including “Phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need”.
globenewswire.com
- 4 months ago
Prima BioMed (IMMP) Loses -34.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Prima BioMed (IMMP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
- 4 months ago
8. Profile Summary
Immutep Limited IMMP
COUNTRY
AU
INDUSTRY
Biotechnology
MARKET CAP
$ 313 M
Dividend Yield
0.00%
Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Contact
Australia Square, Sydney, NSW, 2000
https://www.immutep.com
IPO Date
April 19, 2012
Employees
41
Officers
Mr. Marc Voigt
Chief Executive Officer, MD, Chief Financial Officer, Chief Business Officer & Executive Director
Dr. Frederic Triebel M.D., Ph.D.
Chief Scientific Officer & Executive Director
Mr. Christian Mueller BBA, MSc.
Senior Vice President of Regulatory & Strategy
Ms. Deanne Miller LLB
Chief Operating Officer, General Counsel & Joint Company Secretary
Ms. Indira Naidu
Joint Company Secretary
Dr. Florian D. Vogl M.D., M.Sc., Ph.D.
Chief Medical Officer